{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:28:59Z","timestamp":1791584939439,"version":"4.3.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100006792","name":"Hartwell Foundation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100006792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019451","name":"Uncle Kory Foundation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100019451","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00259-025-07332-w","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T23:38:58Z","timestamp":1747179538000},"page":"4308-4319","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Low-dose temozolomide selectively increases glioblastoma\u2019s vascular permeability, tumor microenvironment penetration and the killing potential of systemic actinium-225 \u03b1-particle dendrimer-radioconjugates improving treatment efficacy"],"prefix":"10.1007","volume":"52","author":[{"given":"Rajiv Ranjit","family":"Nair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aira","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Hariharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen L.","family":"Gabrielson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wathsala","family":"Liyanage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaver M.","family":"Bhujwalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-France Penet","family":"Vidaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rangaramanujam M.","family":"Kannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1735-326X","authenticated-orcid":false,"given":"Stavroula","family":"Sofou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"7332_CR1","doi-asserted-by":"publisher","first-page":"11622","DOI":"10.1038\/s41598-020-68011-4","volume":"10","author":"MTC Poon","year":"2020","unstructured":"Poon MTC, Sudlow CLM, Figueroa JD, Brennan PM. Longer-term (\u2265\u20092 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis. Sci Rep. 2020;10:11622. https:\/\/doi.org\/10.1038\/s41598-020-68011-4.","journal-title":"Sci Rep"},{"key":"7332_CR2","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1002\/cam4.1404","volume":"7","author":"M Liu","year":"2018","unstructured":"Liu M, Thakkar JP, Garcia CR, Dolecek TA, Wagner LM, Dressler EVM, et al. National cancer database analysis of outcomes in pediatric glioblastoma. Cancer Med. 2018;7:1151\u20139. https:\/\/doi.org\/10.1002\/cam4.1404.","journal-title":"Cancer Med"},{"key":"7332_CR3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s11060-020-03408-9","volume":"151","author":"RS D\u2019Amico","year":"2021","unstructured":"D\u2019Amico RS, Aghi MK, Vogelbaum MA, Bruce JN. Convection-enhanced drug delivery for glioblastoma: a review. J Neurooncol. 2021;151:415\u201327. https:\/\/doi.org\/10.1007\/s11060-020-03408-9.","journal-title":"J Neurooncol"},{"key":"7332_CR4","doi-asserted-by":"publisher","unstructured":"Parker NR, Khong P, Parkinson JF, Howell VM, Wheeler HR. Molecular heterogeneity in glioblastoma: potential clinical implications. Front Oncol. 2015;5. https:\/\/doi.org\/10.3389\/fonc.2015.00055.","DOI":"10.3389\/fonc.2015.00055"},{"key":"7332_CR5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1146\/annurev-bioeng-062117-120931","volume":"20","author":"MR McDevitt","year":"2018","unstructured":"McDevitt MR, Sgouros G, Sofou S. Targeted and nontargeted \u03b1-Particle therapies. Annu Rev Biomed Eng. 2018;20:73\u201393. https:\/\/doi.org\/10.1146\/annurev-bioeng-062117-120931.","journal-title":"Annu Rev Biomed Eng"},{"key":"7332_CR6","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1007\/s00259-024-06710-0","volume":"51","author":"RR Nair","year":"2024","unstructured":"Nair RR, Prasad A, Bhatavdekar O, Sarkar A, Gabrielson KL, Sofou S. Combined, yet separate: cocktails of carriers (not drugs) for actinium-225 \u03b1-particle therapy of solid tumors expressing moderate-to-low levels of targetable markers. Eur J Nucl Med Mol Imaging. 2024;51:2649\u201362. https:\/\/doi.org\/10.1007\/s00259-024-06710-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7332_CR7","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.1158\/0008-5472.can-19-0859","volume":"79","author":"BD Yard","year":"2019","unstructured":"Yard BD, Gopal P, Bannik K, Siemeister G, Hagemann UB, Abazeed ME. Cellular and genetic determinants of the sensitivity of Cancer to \u03b1-Particle irradiation. Cancer Res. 2019;79:5640\u201351. https:\/\/doi.org\/10.1158\/0008-5472.can-19-0859.","journal-title":"Cancer Res"},{"key":"7332_CR8","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.2967\/jnumed.121.262992","volume":"63","author":"A Howe","year":"2022","unstructured":"Howe A, Bhatavdekar O, Salerno D, Josefsson A, Pacheco-Torres J, Bhujwalla ZM, et al. Combination of carriers with complementary intratumoral microdistributions of delivered a-Particles May realize the promise for 225Ac in large, solid tumors. J Nucl Med. 2022;63:1223\u201330. https:\/\/doi.org\/10.2967\/jnumed.121.262992.","journal-title":"J Nucl Med"},{"key":"7332_CR9","first-page":"s151","volume":"46","author":"MR Zalutsky","year":"2005","unstructured":"Zalutsky MR. Current status of therapy of solid tumors: brain tumor therapy. J Nucl Med. 2005;46:s151\u20136.","journal-title":"J Nucl Med"},{"key":"7332_CR10","doi-asserted-by":"publisher","unstructured":"Bailly C, Vidal A, Bonnemaire C, Kraeber-Bod\u00e9r\u00e9 F, Ch\u00e9rel M, Pallardy A, et al. Potential for nuclear medicine therapy for glioblastoma treatment. Front Pharmacol. 2019;10. https:\/\/doi.org\/10.3389\/fphar.2019.00772.","DOI":"10.3389\/fphar.2019.00772"},{"key":"7332_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1053\/j.semnuclmed.2020.02.004","volume":"50","author":"C Kratochwil","year":"2020","unstructured":"Kratochwil C, Haberkorn U, Giesel FL. 225Ac-PSMA-617 for therapy of prostate Cancer. Semin Nucl Med. 2020;50:133\u201340. https:\/\/doi.org\/10.1053\/j.semnuclmed.2020.02.004.","journal-title":"Semin Nucl Med"},{"key":"7332_CR12","doi-asserted-by":"publisher","first-page":"130ra46","DOI":"10.1126\/scitranslmed.3003162","volume":"4","author":"S Kannan","year":"2012","unstructured":"Kannan S, Dai H, Navath RS, Balakrishnan B, Jyoti A, Janisse J, et al. Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model. Sci Transl Med. 2012;4:130ra46. https:\/\/doi.org\/10.1126\/scitranslmed.3003162.","journal-title":"Sci Transl Med"},{"key":"7332_CR13","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.biomaterials.2015.02.053","volume":"52","author":"F Zhang","year":"2015","unstructured":"Zhang F, Mastorakos P, Mishra MK, Mangraviti A, Hwang L, Zhou J, et al. Uniform brain tumor distribution and tumor associated macrophage targeting of systemically administered dendrimers. Biomaterials. 2015;52:507\u201316. https:\/\/doi.org\/10.1016\/j.biomaterials.2015.02.053.","journal-title":"Biomaterials"},{"key":"7332_CR14","doi-asserted-by":"publisher","first-page":"e10205","DOI":"10.1002\/btm2.10205","volume":"6","author":"K Liaw","year":"2021","unstructured":"Liaw K, Reddy R, Sharma A, Li J, Chang M, Sharma R, et al. Targeted systemic dendrimer delivery of CSF-1R inhibitor to tumor-associated macrophages improves outcomes in orthotopic glioblastoma. Bioeng Transl Med. 2021;6:e10205. https:\/\/doi.org\/10.1002\/btm2.10205.","journal-title":"Bioeng Transl Med"},{"key":"7332_CR15","doi-asserted-by":"publisher","first-page":"e10160","DOI":"10.1002\/btm2.10160","volume":"5","author":"K Liaw","year":"2020","unstructured":"Liaw K, Zhang F, Mangraviti A, Kannan S, Tyler B, Kannan RM. Dendrimer size effects on the selective brain tumor targeting in orthotopic tumor models upon systemic administration. Bioeng Translational Med. 2020;5:e10160. https:\/\/doi.org\/10.1002\/btm2.10160.","journal-title":"Bioeng Translational Med"},{"key":"7332_CR16","doi-asserted-by":"publisher","first-page":"eabo2652","DOI":"10.1126\/scitranslmed.abo2652","volume":"14","author":"AM Gusdon","year":"2022","unstructured":"Gusdon AM, Faraday N, Aita JS, Kumar S, Mehta I, Choi HA, et al. Dendrimer nanotherapy for severe COVID-19 attenuates inflammation and neurological injury markers and improves outcomes in a phase2a clinical trial. Sci Transl Med. 2022;14:eabo2652. https:\/\/doi.org\/10.1126\/scitranslmed.abo2652.","journal-title":"Sci Transl Med"},{"key":"7332_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.biomaterials.2017.03.035","volume":"130","author":"C Zhu","year":"2017","unstructured":"Zhu C, Sempkowski M, Holleran T, Linz T, Bertalan T, Josefsson A, et al. Alpha-particle radiotherapy: for large solid tumors diffusion Trumps targeting. Biomaterials. 2017;130:67\u201375. https:\/\/doi.org\/10.1016\/j.biomaterials.2017.03.035.","journal-title":"Biomaterials"},{"key":"7332_CR18","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s12192-014-0552-1","volume":"20","author":"XJ Dai","year":"2015","unstructured":"Dai XJ, Li N, Yu L, Chen ZY, Hua R, Qin X, et al. Activation of BV2 microglia by lipopolysaccharide triggers an inflammatory reaction in PC12 cell apoptosis through a toll-like receptor 4-dependent pathway. Cell Stress Chaperones. 2015;20:321\u201331. https:\/\/doi.org\/10.1007\/s12192-014-0552-1.","journal-title":"Cell Stress Chaperones"},{"key":"7332_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12974-016-0596-5","volume":"13","author":"G Casella","year":"2016","unstructured":"Casella G, Garzetti L, Gatta AT, Finardi A, Maiorino C, Ruffini F, et al. IL4 induces IL6-producing M2 macrophages associated to Inhibition of neuroinflammation in vitro and in vivo. J Neuroinflamm. 2016;13:139. https:\/\/doi.org\/10.1186\/s12974-016-0596-5.","journal-title":"J Neuroinflamm"},{"key":"7332_CR20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jconrel.2021.07.018","volume":"337","author":"R Sharma","year":"2021","unstructured":"Sharma R, Liaw K, Sharma A, Jimenez A, Chang M, Salazar S, et al. Glycosylation of PAMAM dendrimers significantly improves tumor macrophage targeting and specificity in glioblastoma. J Control Release. 2021;337:179\u201392.","journal-title":"J Control Release"},{"key":"7332_CR21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11095-019-2745-x","volume":"37","author":"A Al Shoyaib","year":"2019","unstructured":"Al Shoyaib A, Archie SR, Karamyan VT. Intraperitoneal route of drug administration: should it be used in experimental animal studies?? Pharm Res. 2019;37:12. https:\/\/doi.org\/10.1007\/s11095-019-2745-x.","journal-title":"Pharm Res"},{"key":"7332_CR22","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00280-009-1078-6","volume":"65","author":"BD Diez","year":"2010","unstructured":"Diez BD, Statkevich P, Zhu Y, Abutarif MA, Xuan F, Kantesaria B, et al. Evaluation of the exposure equivalence of oral versus intravenous Temozolomide. Cancer Chemother Pharmacol. 2010;65:727\u201334. https:\/\/doi.org\/10.1007\/s00280-009-1078-6.","journal-title":"Cancer Chemother Pharmacol"},{"key":"7332_CR23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2967\/jnumed.108.058651","volume":"51","author":"G Sgouros","year":"2010","unstructured":"Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, et al. MIRD pamphlet 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med. 2010;51:311\u201328. https:\/\/doi.org\/10.2967\/jnumed.108.058651.","journal-title":"J Nucl Med"},{"key":"7332_CR24","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1021\/acs.molpharmaceut.6b00439","volume":"13","author":"S Stras","year":"2016","unstructured":"Stras S, Holeran T, Howe A, Sofou S. Interstitial release of cisplatin from triggerable liposomes enhances efficacy against triple negative breast Cancer solid tumor analogues. Mol Pharm. 2016;13:3224\u201333.","journal-title":"Mol Pharm"},{"key":"7332_CR25","doi-asserted-by":"publisher","unstructured":"Fisher JP, Adamson DC. Current FDA-Approved therapies for High-Grade malignant gliomas. Biomedicines. 2021;9. https:\/\/doi.org\/10.3390\/biomedicines9030324.","DOI":"10.3390\/biomedicines9030324"},{"key":"7332_CR26","doi-asserted-by":"publisher","unstructured":"Kavousanakis M, Bhatavdekar O, Bastiaannet R, Kevrekidis Y, Sofou S. Transport cocktails for Cancer therapeutics. Physical Review Research. 2024;6(3):033137. https:\/\/doi.org\/10.1101\/2024.01.23.576806","DOI":"10.1101\/2024.01.23.576806"},{"key":"7332_CR27","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.2967\/jnumed.121.262992","volume":"63","author":"A Howe","year":"2022","unstructured":"Howe A, Bhatavdekar O, Salerno D, Josefsson A, Pacheco-Torres J, Bhujwalla ZM, et al. Combination of carriers with complementary intratumoral microdistributions of delivered \u03b1-Particles May realize the promise for (225)Ac in large, solid tumors. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2022;63:1223\u201330. https:\/\/doi.org\/10.2967\/jnumed.121.262992.","journal-title":"Soc Nuclear Med"},{"key":"7332_CR28","doi-asserted-by":"publisher","first-page":"e10266","DOI":"10.1002\/btm2.10266","volume":"7","author":"D Salerno","year":"2022","unstructured":"Salerno D, Howe A, Bhatavdekar O, Josefsson A, Pacheco-Torres J, Bhujwalla ZM, et al. Two diverse carriers are better than one: A case study in \u03b1-particle therapy for prostate specific membrane antigen-expressing prostate cancers. Bioeng Translational Med. 2022;7:e10266. https:\/\/doi.org\/10.1002\/btm2.10266.","journal-title":"Bioeng Translational Med"},{"key":"7332_CR29","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.1007\/s00259-021-05406-z","volume":"48","author":"A Prasad","year":"2021","unstructured":"Prasad A, Nair R, Bhatavdekar O, Howe A, Salerno D, Sempkowski M, et al. Transport-driven engineering of liposomes for delivery of \u03b1-particle radiotherapy to solid tumors: effect on Inhibition of tumor progression and onset delay of spontaneous metastases. Eur J Nucl Med Mol Imaging. 2021;48:4246\u201358. https:\/\/doi.org\/10.1007\/s00259-021-05406-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7332_CR30","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.2967\/jnumed.115.171371","volume":"57","author":"K Behling","year":"2016","unstructured":"Behling K, Maguire WF, L\u00f3pez Puebla JC, Sprinkle SR, Ruggiero A, O\u2019Donoghue J, et al. Vascular targeted radioimmunotherapy for the treatment of glioblastoma. J Nucl Med. 2016;57:1576\u201382. https:\/\/doi.org\/10.2967\/jnumed.115.171371.","journal-title":"J Nucl Med"},{"key":"7332_CR31","doi-asserted-by":"publisher","first-page":"9277","DOI":"10.1158\/0008-5472.Can-10-2029","volume":"70","author":"FE Escorcia","year":"2010","unstructured":"Escorcia FE, Henke E, McDevitt MR, Villa CH, Smith-Jones P, Blasberg RG, et al. Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. Cancer Res. 2010;70:9277\u201386. https:\/\/doi.org\/10.1158\/0008-5472.Can-10-2029.","journal-title":"Cancer Res"},{"key":"7332_CR32","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1073\/pnas.1700340114","volume":"114","author":"F Mpekris","year":"2017","unstructured":"Mpekris F, Baish JW, Stylianopoulos T, Jain RK. Role of vascular normalization in benefit from metronomic chemotherapy. Proc Natl Acad Sci U S A. 2017;114:1994\u20139. https:\/\/doi.org\/10.1073\/pnas.1700340114.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7332_CR33","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.nucmedbio.2012.01.011","volume":"39","author":"JM Akudugu","year":"2012","unstructured":"Akudugu JM, Howell RW. A method to predict response of cell populations to cocktails of chemotherapeutics and radiopharmaceuticals: validation with Daunomycin, doxorubicin, and the alpha particle emitter 210Po. Nucl Med Biol. 2012;39:954\u201361. https:\/\/doi.org\/10.1016\/j.nucmedbio.2012.01.011.","journal-title":"Nucl Med Biol"},{"key":"7332_CR34","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1007\/s00259-022-05878-7","volume":"49","author":"S Katugampola","year":"2022","unstructured":"Katugampola S, Wang J, Prasad A, Sofou S, Howell RW. Predicting response of micrometastases with MIRDcell V3: proof of principle with 225Ac-DOTA encapsulating liposomes that produce different activity distributions in tumor spheroids. Eur J Nucl Med Mol Imaging. 2022;49:3989\u201399. https:\/\/doi.org\/10.1007\/s00259-022-05878-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7332_CR35","first-page":"1825","volume":"33","author":"B-A J\u00f6nsson","year":"1992","unstructured":"J\u00f6nsson B-A, Strand S-E, Larsson BS. A quantitative autoradiographic study of the heterogeneous activity distribution of different Indium-111-Labeled radiopharmaceuticals in rat tissues. J Nucl Med. 1992;33:1825\u201333.","journal-title":"J Nucl Med"},{"key":"7332_CR36","doi-asserted-by":"publisher","first-page":"115005","DOI":"10.1016\/j.addr.2023.115005","volume":"200","author":"RM Kannan","year":"2023","unstructured":"Kannan RM, Pitha I, Parikh KS. A new era in posterior segment ocular drug delivery: translation of systemic, cell-targeted, dendrimer-based therapies. Adv Drug Deliv Rev. 2023;200:115005. https:\/\/doi.org\/10.1016\/j.addr.2023.115005.","journal-title":"Adv Drug Deliv Rev"},{"key":"7332_CR37","doi-asserted-by":"publisher","first-page":"4255","DOI":"10.3390\/cancers13174255","volume":"13","author":"RS Andersen","year":"2021","unstructured":"Andersen RS, Anand A, Harwood DSL, Kristensen BW. Tumor-Associated microglia and macrophages in the glioblastoma microenvironment and their implications for therapy. Cancers. 2021;13:4255.","journal-title":"Cancers"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07332-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07332-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07332-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T14:42:40Z","timestamp":1757169760000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07332-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["7332"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07332-w","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"8 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"SS, RRN and RMK are co-inventors in a pending patent involving this work. RMK is a co-founder and former board member of Ashvattha Therapeutics, Inc. Under license agreements involving Ashvattha Therapeutics, Inc and the Johns Hopkins University, RMK and Johns Hopkins University are entitled to royalty distributions related to products discussed in this manuscript. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict-of-interest policies. RMK is an inventor of patents licensed by Ashvattha, relating to the hydroxyl dendrimer-drug compositions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}